Ardelyx

Ardelyx, Inc. (NASDAQ: ARDX) is a biopharmaceutical company based in the United States. The company's business focus is on discovering, developing, and commercializing medicines that act within the gastrointestinal tract to address cardiorenal and metabolic diseases. Its approach targets specific mechanisms at the gut level to influence systemic conditions. The company has developed a pipeline of 27 drug candidates. Its lead commercial product, XPHOZAH® (tenapanor), is approved for the control of serum phosphorus in adults with chronic kidney disease on dialysis. Additionally, IBSRELA® (tenapanor) is approved for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults. These approvals represent the clinical application of Ardelyx's focus on gut-mediated therapies. Ardelyx is a publicly traded entity, having completed four primary funding rounds to support its operations and development programs. The company's research and development efforts continue to advance its portfolio of candidates targeting unmet needs within its core therapeutic areas of cardiorenal and metabolic disorders.